Presentation Outline ICHP Annual Meeting September 13-15

VTE
recurrence
during
study
period
VTE
recurrence
during
study
treatment
WARFASA
Primary Outcome: Recurrence of VTE within 2 years
Aspirin (n=205) Placebo (n=197)
28 43
(6.6% per year) (11.2% per year)
23
(5.9% per year)
N Engl J Med. 2012;366(21):1959-1967.
39
(11.0% per year)
WARFASA
HR with
95% CI
P‐value NNT
HR, 0.58;
95% CI CI,
0.36 to 0.93
PP=0.02 0 02 22
HR, 0.55;
95% CI,
0.33 to 0.92
P=0.02 20
• Results –Post hoc
– Patients with prior PE who had recurrence:
• Aspirin: 6.7% per year
• Placebo: 13.5% per year
• HR, 0.38; 95% CI, 0.17 to 0.88; P=0.02
– Patients with prior DVT who had recurrence:
• Aspirin: 6.5% per year
• Placebo: 10.2% per year
• HR, 0.65; 95% CI, 0.65 to 1.20; P=0.17
N Engl J Med. 2012;366(21):1959-1967.
WARFASA
• Results – Secondary
– Death (any cause)
• Aspirin: 6 patients (1.4% per year)
• Placebo: 5 patients (1.3% per year)
– Arterial events
• Aspirin: 8 patients (including 2 MIs, 2 strokes)
• Placebo: 5 patients (including 2 MIs, 1 stroke)
– Major bleeding
• 1 event in each group
N Engl J Med. 2012;366(21):1959-1967.
8/30/2012
5